HIGHLIGHTS
- who: Clin. Exp. Obstet. Gynecol. et al. from the University, Rome, Italy have published the research work: 2022u037e 49(11): Personalized Treatment of Vulvar Cancer, in the Journal: (JOURNAL) of 10/08/2022
- how: Different studies tried to confirm the safety and feasibility of SLN sparing patients the complications of lymphadenectomy GROINSS-V data showed that in patients with negative biopsy groin recurrence rate was only 2% after almost 3 years and no significative differences with patients with early-stage vulvar cancer treated with groin lymphadenectomy were registered .
SUMMARY
The staging . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.